Multiple Ascending Dose and DDI Study
A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability, And Pharmacokinetics Of Multiple Oral Doses Of Pf-06835919 In Healthy Adult Subjects (Part A); And An Open-label Study To Assess Multiple Oral Doses Of Pf-06835919 On Atorvastatin Pharmacokinetics (Part B)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, B-1070
- Pfizer Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and females (nonchildbearing potential)
- 18 to 55 years old
- Body Mass Index 17.5 to 30.5
Exclusion Criteria:
- Known hereditary fructose intolerance or fructose malabsorption disorder (Part A)
- Statin intolerance (Part B)
- Unable to consume high fructose syrup-containing beverage with each meal while in the unit (Part A)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Tablets administered once or twice daily, with food, in Part A for 14 days.
|
Tablets administered once or twice daily, with food, in Part A.
|
|
Experimental: PF-06835919
Tablets administered once or twice daily, with food, in Part A for 14 days.
Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
|
Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
|
|
Experimental: atorvastatin
In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
|
Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Time Frame: Screening to Day 24
|
Part A
|
Screening to Day 24
|
|
Number of Participants With Clinical Laboratory Abnormalities
Time Frame: Day -2 to Day 24
|
Part A
|
Day -2 to Day 24
|
|
Change from baseline in vital signs
Time Frame: Day -1 to Day 24
|
Part A
|
Day -1 to Day 24
|
|
Change from baseline in 12-lead electrocardiogram
Time Frame: Day -1 to Day 24
|
Part A
|
Day -1 to Day 24
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day -1 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day 3 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day 7 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day -1 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day 3 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day 7 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 3 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Maximum Observed Plasma Concentration (Cmax) on Day -1 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Maximum Observed Plasma Concentration (Cmax) on Day 3 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Maximum Observed Plasma Concentration (Cmax) on Day 7 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Plasma Decay Half-Life (t1/2) on Day -1 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Plasma Decay Half-Life (t1/2) on Day 3 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
|
Plasma Decay Half-Life (t1/2) on Day 7 of atorvastatin and 2 active metabolites
Time Frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Part B
|
0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) on Day 1 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Maximum Observed Plasma Concentration (Cmax) on Day 7 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Maximum Observed Plasma Concentration (Cmax) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48, and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48, and 72 hours post-dose
|
|
|
Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 1 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Apparent Oral Clearance (CL/F) on Day 7 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Apparent Oral Clearance (CL/F) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Minimum Observed Plasma Trough Concentration (Cmin) on Day 7 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Minimum Observed Plasma Trough Concentration (Cmin) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Accumulation Ratio (Rac) on Day 7 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Accumulation Ratio (Rac) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) on Day 7 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
|
|
Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Plasma Decay Half-Life (t1/2) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Apparent Volume of Distribution (Vz/F) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Cumulative Amount of Drug Recovered Unchanged in Urine (Ae) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Percent Cumulative Amount of Drug Recovered Unchanged in Urine (Ae%) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Renal Clearance (CLr) on Day 14 Part A
Time Frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
|
|
|
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Time Frame: Screening to Day 18
|
Part B
|
Screening to Day 18
|
|
Number of Participants With Clinical Laboratory Abnormalities
Time Frame: Day -2 to Day 18
|
Part B
|
Day -2 to Day 18
|
|
Change from Baseline in Vital Signs
Time Frame: Day -2 to Day 18
|
Part B
|
Day -2 to Day 18
|
|
Change from baseline in 12-lead electrocardiogram
Time Frame: Day -2 to Day 18
|
Part B
|
Day -2 to Day 18
|
|
Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 7 Part A
Time Frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
0,0.5,1,2,4,5,6,8 and 12 hours post-dose
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- C1061002
- 2016-004649-10 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.